Should Digoxin Be Held in a Patient with Seizure?
No, digoxin should not be routinely held in a patient who has experienced a seizure, unless there is evidence of digoxin toxicity or the seizure is directly attributable to digoxin overdose. The available evidence does not support seizures as a contraindication to continuing digoxin therapy in patients taking therapeutic doses.
Clinical Decision Framework
1. Assess for Digoxin Toxicity First
The key question is whether the seizure is related to digoxin toxicity or an independent neurological event:
Check immediately:
- Serum digoxin level (therapeutic range: 0.5-1.0 ng/mL; toxicity typically >2 ng/mL but can occur at lower levels) 1, 2
- Serum potassium - hypokalemia increases digoxin toxicity risk 1, 2
- Serum magnesium - hypomagnesemia increases toxicity risk 1, 2
- Renal function - impaired clearance elevates digoxin levels 1, 3
- Other signs of digoxin toxicity: visual disturbances, confusion, disorientation, nausea, anorexia, cardiac arrhythmias 1, 2
2. Digoxin-Related Seizures Are Rare
Neurological toxicity from digoxin typically manifests as confusion, disorientation, and visual disturbances—not seizures 1, 2. The FDA label lists "confusion, disorientation, and visual disturbances" as neurological adverse effects but does not list seizures as a recognized manifestation of digoxin toxicity 4.
While experimental research shows digoxin can induce seizures in animal models at toxic doses 5, this is not a clinically recognized presentation in humans at therapeutic levels. Paradoxically, recent research suggests digoxin at sub-cardiotonic doses may actually have anticonvulsant properties and can enhance the effect of traditional antiepileptic drugs 6, 7, 8.
3. When to Hold Digoxin
Hold digoxin if:
- Serum digoxin level >2 ng/mL 1, 2
- Clinical signs of digoxin toxicity are present (visual changes, severe nausea/vomiting, confusion, cardiac arrhythmias) 1, 4
- Severe hyperkalemia is present (digoxin toxicity can cause massive potassium shift) 4
- Significant bradycardia or heart block develops 1, 4
Continue digoxin if:
- Digoxin level is therapeutic (0.5-1.0 ng/mL)
- No clinical signs of toxicity
- Electrolytes are normal
- Seizure appears unrelated to digoxin (e.g., known seizure disorder, other provoking factors)
4. Management Algorithm
If seizure occurs in patient on digoxin:
- Stabilize the patient - treat the seizure per standard protocols 9
- Draw digoxin level and electrolytes immediately
- Review medication list for drug interactions that increase digoxin levels: amiodarone, verapamil, clarithromycin, erythromycin, itraconazole, cyclosporine, quinidine 1, 10, 2
- Assess renal function - elderly patients and those with renal impairment are at higher risk 1, 3
If digoxin toxicity is confirmed:
- Temporarily discontinue digoxin 4
- Correct electrolyte abnormalities (potassium, magnesium) 1, 4
- Consider digoxin-specific antibody fragments (Digibind) for life-threatening toxicity 4, 11
- Monitor cardiac rhythm
If no evidence of toxicity:
- Continue digoxin at current dose
- Investigate other causes of seizure
- Monitor digoxin level and renal function more frequently 3
Important Caveats
- Elderly patients (>70 years) require lower doses (0.125 mg daily or every other day) and closer monitoring 1, 2
- Renal dysfunction significantly increases toxicity risk - consider dose reduction or holding if creatinine increases >30% from baseline 3
- Drug interactions are common and can precipitate toxicity even at previously therapeutic doses 1, 10
- Toxicity can occur at therapeutic serum levels, especially with hypokalemia, hypomagnesemia, or hypothyroidism 1, 12
The decision to hold digoxin should be based on evidence of toxicity, not simply the occurrence of a seizure. Most seizures in patients taking digoxin are unrelated to the medication and do not warrant discontinuation if levels are therapeutic and no other signs of toxicity exist.